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Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions
such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We
investigated the eﬃcacy of rikkunshito (TJ-43) on CINV. Methods. Nineteen patients who were going to undergo DFP therapy
were enrolled. They were assigned to the following two groups: a TJ-43-treated group and -nontreated group. The following
parameters were compared between the 2 groups: (1) the frequency of symptoms occurred, (2) vomiting, nausea, and anorexia
score, and (3) QOL score. Results. The incidence of symptoms was lower in the TJ-43-treated group than that in the control group.
The nausea score of the TJ-43-treated group was signiﬁcantly lower than that of the control group. In the QOL score, the mood
score and the ADL score decreased signiﬁcantly in the control group. Conclusion. We recommend TJ-43 administration in patients
undergoing DFP chemotherapy.
1.Introduction
Esophageal cancer is a highly malignant neoplasm with poor
prognosis. The mortality of this disease is 9.0 per 100,000
(15.7 per 100,000 in males, 2.6 in females), representing
3.4% (4.9% in males, 1.3% in females) of all deaths by
malignant neoplasm in 2006. Mortality has increased slightly
over the past two decades despite recent improvements in
diagnosis and treatment [1]. The esophagus has complicated
relations not only with the nearby organs such as trachea,
lung, and aorta but also with the lymphatic tissue network.
Therefore, the cancer generated at the esophagus shows
easily lymph node metastasis in the wide range from the
cervical region to the abdominal region even when it is
as u p e r ﬁ c i a lc a n c e r[ 2]. This is why surgical intervention
accompanied by extensive lymph node dissection has been
performed for the radical treatment of esophagus cancer
[3]. Since the invasion accompanying such radical surgery
gives marked inﬂuences on the postoperative quality of life
(QOL) [4], the importance of multidisciplinary approach
including surgery/chemotherapy/radiotherapy is being rec-
ognized more and more to achieve successful radical therapy.
Japan clinical oncology group (JCOG) conducted a phase
II study of chemoradiotherapy in patients with stage II, III
esophageal carcinoma (ESCC): (JCOG9906 study), but the
result showed lesser than the surgical results of Japanese
high-volume centers [5]. The eﬀect of chemotherapy on
esophagus cancer has already been demonstrated [6], and
it was recently reported that preoperative chemotherapy is
moreeﬀectivethanpostoperativechemotherapy[7].Wehave
actively performed DFP therapy as preoperative chemother-
apy and obtained favorable results, but leukocytopenia and
alopecia and also gastrointestinal adverse reactions such as
vomiting, nausea, and anorexia (so-called chemotherapy-
induced nausea and vomiting: CINV) interfere often with
continuation of the chemotherapy [8]. To alleviate for
CINV, a steroid preparation, a 5-HT3 antagonist, and a
gastrointestinal complaint-treating agent are used, but these2 International Journal of Surgical Oncology
drugs are not satisfactory in the light of eﬃcacy and safety,
and there is also a problem in the aspectof medical economy.
Recently in Japan, the kampo preparation rikkunshito
(TJ-43) having a gastrointestinal motility-improving eﬀect is
oftenusedforthetreatmentofvomiting,nausea,oranorexia.
Tomono et al. reported the eﬀect of TJ-43 on retching occur-
ring during breast cancer chemotherapy [9]. It is therefore
expected that TJ-43 would exert an alleviating eﬀect for the
CINV caused by DFP therapy. However, few papers have
clearly referred to the eﬀect of TJ-43 on vomiting, nausea, or
anorexia occurring during chemotherapy. In this study, for
the purpose of improving the QOL of patients undergoing
chemotherapy, we investigated the eﬃcacy and safety of
TJ-43inthetreatmentofadversereactions(vomiting,nausea
or anorexia) to DFP therapy in patients with advanced
esophagus cancer.
2. Methods
This study was approved by the Ethics Committee of
Tokushima University Hospital and conducted in compli-
ance with the ethical principle of the Helsinki Declaration.
2.1.StudyPatients. IntheperiodfromAugust2008toMarch
2009, 19 patients with advanced esophagus cancer (age: 52–
79 years, disease stage: II or III) who were going to undergo
DFP therapy submitted written informed consent to par-
ticipate in this study after receiving suﬃcient explanations
about the contents of this study. The ECOG Performance
Scale needed to be 0–2 in these patients. The exclusion
criteria were as follows: (1) patients who had undergone
gastrectomy or endoscopic gastrostomy, (2) patients with
renal dysfunction, cardiac dysfunction, or bone-marrow
dysfunction, (3) patients with serious complication such as
cardiac failure or acute inﬂammatory disease, (4) female
patients who were pregnant, planning pregnancy, or breast-
feeding, and (5) patients taking other kampo drug excluding
rikkunshito.
2.2. Drugs. Rikkunshito, one of traditional Japanese med-
icines, which has been approved for medicinal use by the
Japanese Ministry of Health and Welfare, is extract granules
for Ethical Use (Tsumura and Co., Product number TJ-43,
7.5g), containing 4.0g of dried extract obtained from mixed
crude drugs in the following ratio: JP Atractylodes Lancea
Rhizome, 4.0g; JP Ginseng, 4.0g; JP Pinellia Tuber, 4.0g;
JP Poria Sclerotium, 4.0g; JP Jujube, 2.0g; JP Citrus Unshiu
Peel,2.0g;JPGlycyrrhiza,1.0g;andJPGinger,0.5g.Subjects
took 2.5g of rikkunshito three times a day before each
meal.
2.3. Study Design. The basic chemotherapy in this study was
DFP therapy, which was performed according to the regimen
speciﬁed at this hospital for advanced esophagus cancer. In
detail, CDDP 10mg/body was intravenously infused on days
1–5, 5-FU 370mg/m2 was intravenously infused on days
1–5, docetaxel 25mg/m2 was intravenously infused on day
1 and day 8 in each cycle, and this cycle was repeated 4
times. This study was conducted in the period from day
1 to day 14. As antiemetic drugs, azasetron 10mg/day was
intravenously infused on days 1–5 and dexamethasone 8mg
was intravenously infused on Day 1.
Subjects were randomly assigned to the TJ-43-treated
group and the TJ-43-non-treated group (the control group).
In the TJ-43-treated group, TJ-43 was orally administered
from Day 1 for 2 weeks. All the subjects were inquired
about the symptoms on Days 1–5, Day 8, and Day 14.
The investigators who assessed severity and QOL were not
informed which group the patients belonged to.
2.4. Eﬃcacy Evaluation. The primary index was the change
in each symptom (vomiting, nausea, or anorexia) 2 weeks
after the TJ-43 treatment. The symptom severity was eval-
uated with CTCAE Version 3.0 on days 1–5, day 8, and day
14. For comparison between the 2 groups, the CTCAE grade
was scored according to the following rules: no symptoms: 0
point, and CTCAE grade 1–4: 1 point-4 point.
As the secondary index, the eﬀect of TJ-43 treatment
on QOL was evaluated on Day 1 and Day 14. Five items
of sleep, mood, volition, activity of daily living (ADL), and
anxiety feeling were set for QOL scoring. Each item was
scored on the ﬁve-grade scale of 1–5 according to QOL-ACD
[10]( Figure 1). Almost patients ﬁlled out question paper by
themselves. But some patients could not ﬁll it because of bad
condition; so the investigator asked symptoms showing the
interview sheet and ﬁlled it for them. The assessment was
done by the doctor who did not participate in this study.
2.5. Safety Evaluation. An adverse event was deﬁned as any
unfavorable or unintended sign, whether or not considered
to be causally related to the study drug, and was recorded
in the medical record. On day 14, the patients answered the
standardized question: “Have you had any health problems
since you started to take the study drug”?
2.6. Statistical Analysis. In order to summarize the subject
information before the treatment, the subject background
factors and the summary statistics of the evaluation items on
Day1wereobtainedforallthesubjectsassigned.Onesubject
who deviated from the age-related inclusion criterion was
not included in the eﬃcacy analysis. The diﬀerences between
Day 1 and Day 14 were subjected to calculation of summary
statisticsandintergroupcomparisonbyWilcoxon’sranksum
test. The diﬀerences were tested for signiﬁcance with a two-
sided signiﬁcance level of 5%. The intragroup comparison
between Day 1 and Day 14 was performed by Wilcoxon’s
signed rank test. No adjustment was made for multiple
tests.
3. Results
No subjects reported vomiting, nausea, or anorexia before
the assignment. One subject of the TJ-43 treated group was
excluded from evaluation due to deviation from the age-
related inclusion criterion (Figure 2).International Journal of Surgical Oncology 3
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Figure 1: Interview sheet of QOL.
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Figure 2: Enrollment and randomization of study patients.
There were no diﬀerences between the two groups in
male/female ratio, age, and BMI of the subjects (Table 1).
3.1. Incidence of Symptoms. Table 2 shows the number and
rate of subjects who reported vomiting, nausea, or anorexia
in each group. The incidence of vomiting, nausea, or
anorexia was lower in the TJ-43 treated group than that in
the TJ-43 non-treated group. In the TJ-43-treated group, 3
of 8 subjects presented with vomiting, nausea or anorexia on
Day 14. On the other hand, in the TJ-43 non-treated group,
8 of 10 subjects had vomiting, nausea, or anorexia on Day
14,butthesymptomincidencewasnotsigniﬁcantlydiﬀerent
between the 2 groups.
3.2. Time-Course Changes in Score of Vomiting, Nausea, or
Anorexia. The increase of nausea score was signiﬁcantly
suppressed in the TJ-43 treated group as compared with
TJ-43 non-treated group (0.50 ± 0.76 versus 1.80 ± 1.23
on day 14) (Figure 3). The increases of vomiting score and
anorexia score tended to be suppressed in the TJ-43 treated
group as compared with the TJ-43 non-treated group, but
no signiﬁcant inter-group diﬀerence was observed (Figures 4
and 5).
3.3. Time-Course Changes in Score of QOL. Among the
QOL scores, the mood score decreased signiﬁcantly from
3.50 ± 0.53 on day 1 to 1.89 ± 1.05 on day 14 in the
TJ-43 non-treated group but showed no change in the TJ-43
treated group (Figure 6). Similarly, the ADL score decreased
signiﬁcantlyfrom4.10 ±0.74onDay1to2.89 ±1.05onDay
14intheTJ-43non-treatedgroup(Figure 7).Thediﬀerences
between Day 1 and Day 14 in mood score and ADL score
weresigniﬁcantlylowerintheTJ-43treatedgroupthanthose
in the TJ-43 non-treated group (Figure 8). The changes in
scoresofsleep,volition,andanxietyfeelingwerenotdiﬀerent4 International Journal of Surgical Oncology
Table 1: Demographic and medical characteristics of the study
patients.
TJ-43-treated
group (n = 9)
TJ-43-nontreated
group (n = 10)
Sex (male/female) 8/1 7/3
Age (mean ± SD) 63 ± 6.2 68.1 ± 7.3
BMI (mean ± SD) 21.9 ± 1.9 21.2 ± 3.3
Clinical stage
II A 1 1
II B 1 0
III 2 7
IV 5 2
Performance status
09 9
10 1
Table 2: Frequency of vomiting, nausea, and anorexia at 14 days.
TJ-43 treated
group N (%)
TJ-43 nontreated
group N (%)
Vomiting Not reported 7 (87.5) 6 (60.0)
Reported 1 (12.5) 4 (40.0)
Nausea Not reported 5 (62.5) 2 (20.0)
Reported 3 (37.5) 8 (80.0)
Anorexia Not reported 5 (37.5) 3 (30.0)
Reported 3 (62.5) 7 (70.0)
between the TJ-43 treated group and the TJ-43 non-treated
group.
3.4. Adverse Events. In the study period, none of the subjects
developed any potential adverse reactions to TJ-43.
3.5. Therapeutic Eﬀect of DFP Therapy. Looking at the
therapeutic eﬀect of DFP therapy (Cycle 1), CR was seen in
2 subjects, PR in 5 subjects, and SD in 1 subject in the TJ-43
treated group, and CR in 3 subjects, PR in 5 subjects, and SD
in 2 subjects in the TJ-43 non-treated group.
4. Discussion
This is the ﬁrst prospective randomized study that demon-
strated the eﬃcacy of TJ-43 against CINV accompanying
DFP therapy in patients with advanced esophagus cancer.
Esophagus cancer is one of the malignant tumors
encountered frequently and ranked seventh among the
cancer-related causes of death in the world [11]. It is one
of the intractable cancers. Esophagectomy accompanied by
extensive lymph node dissection is the standard therapy, but
the 5-year survival rate achieved by this surgery alone was
reported to be only 10%–20% in the advanced cases [12–
14]. In the advanced cases, the possibility of recurrence is
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Figure 3: Time-course changes in score of nausea. Each plot refers
to mean ± SD. ∗: Signiﬁcant diﬀerence of the score deterioration
between the TJ-43 treated group and the TJ-43 non-treated group
(P< 0.05, Wilcoxon’s rank sum test).
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Figure 4: Time-course changes in score of vomiting. Each plot
refers to mean ± SD. There were no signiﬁcant diﬀerences in score
change between the TJ-43 treated group and the TJ-43 non-treated
group (Wilcoxon’s rank sum test).
high even after radical resection, and the therapeutic eﬀectof
surgical therapy alone is insuﬃcient. It is therefore necessary
to perform eﬀective perioperative management therapy for
achieving successful radical therapy, and as the standard
therapy against esophagus cancer, FP therapy using CDDP
and 5-FU was proposed [15, 16]. Furthermore in recent
years, FP therapy added with docetaxel (DFP therapy) was
reported to give a higher response rate [17–19]a n dw e
also obtained favorable results in patients with esophagus
cancer [20, 21]. However, whereas DFP therapy is more
eﬀective than FP therapy, DFP therapy often induces notInternational Journal of Surgical Oncology 5
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Figure 5:Time-coursechangesinscoreofanorexia.Eachplotrefers
to mean ± SD. There were no signiﬁcant diﬀerences in score change
between the TJ-43 treated group and the TJ-43 non-treated group
(Wilcoxon’s rank sum test).
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Figure 6: Change in score of mood. Each plot refers to mean ± SD.
∗Signiﬁcant diﬀerence between the score on day 1 and day 14 in the
TJ-43 non-treated group (P<0.05, Wilcoxon’s signed rank test).
only leukocytopenia and alopecia but also gastrointestinal
symptoms such as vomiting, nausea, and/or anorexia. CINV
are common adverse reactions of chemotherapy, but they
are considered by patients to be one of the most distressing
concerns of cancer treatment [22, 23]. The failure in
prevention of CINV in the ﬁrst cycle of chemotherapy
increasesthepatient’sresistancetothechemotherapyleading
to abandonment of cancer therapy [24, 25]. Therefore,
CINV control is the key point for successful completion of
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Figure 7: Changes in score of ADL. Each plot refers to mean ± SD.
∗Signiﬁcant diﬀerence between the score on day 1 and day 14 in the
TJ-43 non-treated group (P< 0.05, Wilcoxon’s signed rank test).
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Figure 8: Change in QOL score of mood or ADL after the 2-week
treatment. Each column represents the mean ± SD. ∗Signiﬁcant
diﬀerence of the change in QOL score between the TJ-43 treated
group and the TJ-43 non-treated group (P<0.05, Wilcoxon’s rank
sum test).
chemotherapy and QOL maintenance in the patients. CINV
is roughly classiﬁed into acute, delayed, and anticipatory
types depending on the onset timing of vomiting [26].
The symptoms occurring in the ﬁrst 24hours after starting
the chemotherapy are deﬁned as acute CINV and can be
controlled with an antiemetic drug. On the other hand, the
delayed CINV occurring more than 24hours after starting
the chemotherapy show a lower incidence as compared with6 International Journal of Surgical Oncology
the acute CINV but are diﬃcult to control [27]. In order to
control the delayed CINV, a dopamine antagonist, a steroid,
a 5-HT3 antagonist and an NK1 receptor antagonist are
used alone or in combination in a preventive manner from
before starting the chemotherapy [28], but the eﬀect is not
necessarily satisfactory. Then, the second-generation 5-HT3
antagonist and NK1 receptor antagonist have been used only
for a short period yet in Japan, and besides, these drugs
are expensive, with problem in view of medical economics.
To complete chemotherapy while maintaining the patient’s
QOL, it is desirable to establish a convenient and eﬀective
treatment method.
This time, we focused on a kampo drug TJ-43, which is
frequently used not only against functional dyspepsia, gas-
troesophageal reﬂux disease, and gastrointestinal symptoms
after surgery but also against gastrointestinal symptoms such
as nausea and vomiting induced by a psychotropic drugs or
anticancer drugs [29–33]. So, we investigated the possibility
of TJ-43 as an antiemetic drug. As a result, the incidences
of CINV or anorexia tended to be lower in the TJ-43
treated group, and especially TJ-43 treatment signiﬁcantly
suppressed the incidence of nausea. Furthermore, the QOL
deterioration in terms of mood or ADL was suppressed
by the TJ-43 treatment. These results suggested that oral
administration of TJ-43 would alleviate the unpleasant
symptoms in patients undergoing chemotherapy. The fact
that the diﬀerence in intensity of CINV between the TJ-43
treated group and the TJ-43 non-treated group became
greater with increasing time after starting the treatment
suggested the eﬃcacy of TJ-43 against the delayed CINV
refractory to a 5-HT3 antagonist.
As the action mechanism supporting the clinical eﬀect
of TJ-43, Tominaga et al. clariﬁed that TJ-43 enhances
gastric motility through the 5-HT3 receptor-antagonistic
eﬀect and speculated that the eﬀect is mediated by a signal
transmission route diﬀerent from that for 5-HT3 receptor-
antagonist [34]. If TJ-43 has such speciﬁc eﬀect, it may be
possible to explain the reason why TJ-43 can alleviate the
CINV induced by serotonin in the case of cisplatin, and so
forth; especially the delayed CINV are resistant to a 5-HT3
antagonist. To investigate usefulness of TJ-43 is required for
diﬀerent regimens of chemotherapy and for variety of cancer
types hereafter.
Our study was performed as a pilot study to conduct a
future large-scale randomized controlled trial. There may be
a limitation of statistical conﬁdence in this study, because
number of subjects was small. However, even among the
small number of subjects, there was a signiﬁcant diﬀerence.
Therefore, we consider that the results are worth reporting.
In this study, the eﬃcacy of TJ-43 against CINV was
showninesophaguscancerpatientsundergoingpreoperative
chemotherapy (DFP therapy). The add-on treatment with
TJ-43 not only suppressed the increase of nausea score
but also maintained the patient’s mood and ADL. We
propose to use TJ-43 together with a 5HT3 antagonist, a
steroid, an NK1 receptor antagonist, and so forth as one of
the anti-CINV treatment strategies in patients undergoing
chemotherapy.
Abbreviations
TJ-43: Rikkunshito
DFP: Docetaxel/5-FU/CDDP
QOL: Quality of life
JCOG: Japan clinical oncology group
CINV: Chemotherapy-induced nausea and vomiting
ADL: Activities of daily living.
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